What's new in DyslipidemiaLast update of the site: Tuesday September 20, 2022
Gitto, Mauro MD et al. | Journal of Cardiovascular Pharmacology...
Type 2 diabetes mellitus is a leading cause of morbidity and mortality worldwide, affecting nearly 10%...
Akilli, Rabia MD et al. | Menopause 2022; 29(8): 905-10
Atherosclerotic cardiovascular disease (ASCVD) is the most common cause of death in postmenopausal women.1,2...
Oggero, Silvia et al. | Journal of Hypertension 2022; 40(8):...
Extracellular vesicles have been proposed as potential biomarkers of cardiovascular risk [1-3]. Compared...
Faletra Agostino et al. | BMC Musculoskeletal Disorders 2022;...
Patients with musculoskeletal disorders frequently present with significant cardiovascular risk factors...
Georgakis Marios K. et al. | BMC Medicine 2022; 20(1): 245
Chronic inflammation is an emerging therapeutic target for cardiovascular disease (CVD) [1]. Among pharmacological...
Maria Maddalena
D'Errico
et al. | European Journal of Clinical Investigation...
The CHADS score was introduced in 2006 by the ACC/AHA/ESC guidelines for the management of patients with...
Yun Jae-Seung et al. | Cardiovascular Diabetology 2022; 21(1):...
Cardiovascular disease (CVD) is one of the leading causes of mortality, and has become a global public...
Dongxue
Zhang
et al. | Journal of Periodontal Research 2022;...
According to the International Diabetes Federation, in 2015, an estimated 415 million people were...
Faizan
Mazhar
PharmD et al. | Journal of the American Heart Association...
Both adherence and treatment intensity can alter the effectiveness of lipid‐lowering therapy (LLT)...
Louisa Bloudeau et al. | Pediatric Nephrology 2022; aop: 10.1007/s00467-022-05636-9...
X-linked hypophosphatemia (XLH) is an orphan genetic disease most commonly associated with an inactivating...